国际肿瘤学杂志最新文献

{"title":"Research progress of cancer stem cells in triple-negative breast cancer","authors":"Ye Kang, Jianyi Li, Xiang-Hong Yang","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.06.010","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.06.010","url":null,"abstract":"There are abundant cancer stem cells (CSCs) in triple-negative breast cancer (TNBC). CSCs can maintain their phenotype by unique molecular mechanism and tumor microenvironment, and can promote the chemotherapy resistance and recurrence of TNBC. Blocking these key molecules or altering tumor microenvironment can reduce CSCs, and then inhibited cancer growth and reverse chemotherapy resistance of TNBC. \u0000 \u0000 \u0000Key words: \u0000Breast neoplasms; Neoplastic stem cells; Therapy; Drug resistance; Triple negative breast neoplasms","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"44 1","pages":"362-365"},"PeriodicalIF":0.0,"publicationDate":"2019-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73223308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of circular RNAs in colorectal cancer","authors":"Guodong Yang","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.06.015","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.06.015","url":null,"abstract":"The occurrence and development of colorectal cancer are regulated by many factors and circular RNAs are also involved. The studies have shown that some circular RNAs have high sensitivity and specificity in the diagnosis of colorectal cancer, and have a certain promoting effect on liver and lung metastasis of colorectal cancer involved in signal transduction, DNA repair. The expressions of some circular RNAs are related to the survival time of patients. In addition, down-regulation of partial circular RNAs enhances radiosensitivity of colorectal cancer cells and participates in a variety of tumor-associated signaling pathways in chemotherapeutic-resistant colorectal cancer cells . \u0000 \u0000 \u0000Key words: \u0000Colorectal neoplasms; RNA","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"34 1","pages":"382-384"},"PeriodicalIF":0.0,"publicationDate":"2019-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87206936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expression and mechanisms of long non-coding RNAs SNHG15 in cancers","authors":"Yingying Li","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.06.006","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.06.006","url":null,"abstract":"As a kind of long non-coding RNAs (lncRNAs), small nucleolar RNA host gene 15 (SNHG15) is located on chromosome 7. In recent years, studies have shown that lncRNA SNHG15 is over expressed in various types of cancers such as glioma, thyroid cancer, breast cancer, lung cancer, gastric cancer, colorectal cancer, liver cancer, renal carcinoma, pancreatic cancer, osteosarcoma, and it can promote the proliferation, invasion, metastasis of malignant tumors and lead to poor prognosis of tumor patients through different signal pathways. \u0000 \u0000 \u0000Key words: \u0000RNA, long noncoding; Neoplasms; Small nucleolar RNA host gene 15","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"5 1","pages":"346-349"},"PeriodicalIF":0.0,"publicationDate":"2019-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83988020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical observation of early-stage breast cancer after breast-conserving surgery with hypofractionated radiotherapy","authors":"Linjing Zheng, Dong Yang, Bing Hu, Yinping Dong, Lijun Sun, C. Xia, Baosheng Li, Wei Huang","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.06.003","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.06.003","url":null,"abstract":"Objective \u0000To observe the long-term effect, adverse reaction and cosmetic outcome of early-stage breast cancer with hypofractionated whole-breast irradiation (HF-WBI) after breast-conserving surgery. \u0000 \u0000 \u0000Methods \u0000A total of 206 patients with stage 0-Ⅱ breast cancer after breast-conserving surgery were included in Shandong Cancer Hospital Affiliated to Shandong University from May 2014 to August 2017. According to radiotherapy fraction, patients were divided into HF-WBI group and conventional whole-breast irradiation (CF-WBI) group. In HF-WBI group, 116 patients received whole-breast radiation to 42.56 Gy in 16 fractions followed by tumor bed boost of 9 Gy in 3 fractions or 10 Gy in 5 fractions. In CF-WBI group, 90 patients received whole breast radiation to 50 Gy in 25 fractions followed by tumor bed boost of 10 Gy in 5 fractions. The 2-year local recurrence rate, 2-year mortality rate, acute adverse reaction, late adverse reaction and cosmetic outcome of the two groups were analyzed. \u0000 \u0000 \u0000Results \u0000The 2-year local recurrence rates of HF-WBI group and CF-WBI group were 0.86% (1/116) and 2.22% (2/90) respectively, and there was no significant difference between the two groups (χ2=0.049, P=0.824). The 2-year mortality rates of the two groups were 0.86% (1/116) and 0 (0/90) respectively, and there was no significant difference (P>0.999). There were 108 cases (93.1%) in HF-WBI group and 84 cases (93.3%) in CF-WBI group with grade 0-1 acute dermatitis, and 8 cases (6.9%) and 6 cases (6.7%) with grade 2-3 respectively, with no statistically significant difference (χ2=0.004, P=0.948). There were 97 cases (83.6%) in HF-WBI group and 79 cases (87.8%) in CF-WBI group with grade 0-1 bone marrow suppression, and 19 cases (16.4%) and 11 cases (12.2%) with grade 2-4 respectively, with no statistically significant difference (χ2=0.704, P=0.401). In the two groups, there were 1 case (0.9%) and 3 cases (3.3%) with grade 1-2 radiation pneumonitis, and 115 cases (99.1%) and 87 cases (96.7%) with no radiation pneumonitis respectively, and the difference was not statistically significant (χ2=1.626, P=0.202). There was 1 case (0.9%, 1.1%) with grade 1 breast edema in each group, and 115 cases (99.1%) and 89 cases (98.9%) did not occur breast edema, with no statistically significant difference (χ2=0.033, P=0.857). In the late adverse reactions, there were 5 cases (4.3%) and 3 cases (3.3%) with skin pigmentation in HF-WBI group and CF-WBI group respectively. There were 2 cases (1.7%, 2.2%) with grade 1 subcutaneous tissue fibrosis in each group, and there were 1 case (0.8%) and 2 cases (2.2%) with grade 1 pulmonary fibrosis respectively. The differences between the two groups were not statistically significant (χ2=0.000, P>0.999; χ2=0.000, P>0.999; χ2=0.049, P=0.824). The 6-month, 1-year and 2-year cosmetic outcome good rates in HF-WBI and CF-WBI group were 96.5% (111/115) and 93.3% (84/90), 92.1% (105/114) and 90.0% (81/90), 91.4% (53/58) and 87.2% (41/47) respectivel","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"26 1","pages":"331-336"},"PeriodicalIF":0.0,"publicationDate":"2019-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82267725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expression of DLL3 in small cell lung cancer and its application in targeted therapy","authors":"H. Zuo, Na Li, Luojun Chen, Hua-li Liu","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.06.011","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.06.011","url":null,"abstract":"Small cell lung cancer (SCLC) has a poor biological behavior, high probability of recurrence and metastasis, and limited treatment. The Notch signaling pathway is an evolutionarily conserved pathway that regulates the growth of many cell types through local cell-cell interactions. It controls the differentiation, proliferation and survival of cells. As a ligand for the Notch pathway, delta-like protein 3 (DLL3) is highly expressed on the membrane of SCLC cells. DLL3 plays an important role in cancer initiation and epithelial mesenchymal transition, invasion and metastasis of SCLC. Rovalpituzumab tesirine is a conjugate of directed against DLL3, which shows great potential for SCLC therapy. \u0000 \u0000 \u0000Key words: \u0000Small cell lung carcinoma; Receptors, Notch; Delta-like protein 3","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"68 1","pages":"366-369"},"PeriodicalIF":0.0,"publicationDate":"2019-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75393336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of functional imaging technology in radiotherapy for lung cancer","authors":"Meili Hao, L. Sun, Xiao-Ji Ding","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.06.012","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.06.012","url":null,"abstract":"Functional imaging plays an important role in lung cancer radiotherapy. Functional imaging techniques include single photon emission computed tomography, positron emission tomography, magnetic resonance imaging, and computed tomography. Using lung function information provided by these techniques for lung cancer radiotherapy can better protect the normal function of lung tissue, optimize the radiotherapy program, and reduce the incidence of radiation pneumonitis. With the development of perfusion and imaging technology, functional imaging technology is expected to be widely used in the precise radiotherapy of lung cancer in the future. \u0000 \u0000 \u0000Key words: \u0000Lung neoplasms; Radiotherapy; Functional lung imaging","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"43 1","pages":"370-373"},"PeriodicalIF":0.0,"publicationDate":"2019-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81128371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of metronomic chemotherapy in the treatment of advanced non-small cell lung cancer","authors":"Qingqing Zhu, C. Xie, B. Song, Qiujing Zhang, Jie Liu","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.06.013","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.06.013","url":null,"abstract":"Metronomic chemotherapy is a brand-new and multi-target chemotherapy strategy. Totally different from the traditional chemotherapy, metronomic chemotherapy can exert synergistic and durable anti-tumor effects via multiple mechanisms, including cytotoxic effect, anti-angiogenesis, immune regulation and so on. Single and combined therapy modes of metronomic oral vinorelbine have good curative effects and safeties for the treatment of advanced non-small cell lung cancer. With the in-depth understanding of metronomic chemotherapy, it will certainly become an important treatment mode for advanced non-small cell lung cancer. \u0000 \u0000 \u0000Key words: \u0000Carcinoma, non-small-cell lung; Chemoradiotherapy; Drug therapy, combination; Metronomic chemotherapy; Vinorelbine","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"95 1","pages":"374-377"},"PeriodicalIF":0.0,"publicationDate":"2019-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76152834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application value of serum LDH in advanced non-small cell lung cancer patients treated with EGFR-TKI","authors":"Liping Zheng, Yi-de Chen, Nan Zhang, Wen Quan, Junxiang Du, Cuiwei Liang","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.06.004","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.06.004","url":null,"abstract":"Objective \u0000To investigate the value of serum lactate dehydrogenase (LDH) in advanced non-small cell lung cancer (NSCLC) treated with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI). \u0000 \u0000 \u0000Methods \u0000Pretreatment LDH level, pathological characteristic, tumor staging and treatment situation of 190 advanced NSCLC patients with EGFR sensitive mutation confirmed by pathology were retrospectively collected in Zhuhai People′s Hospital of Guangdong Provice from July 2011 to July 2015. All the patients were divided into LDH normal group (LDH≤252 U/L, n=78) and elevated group (LDH>252 U/L, n=112) according to pretreatment LDH level. Imaging evaluations of the patients were performed regularly, and the progression-free survival (PFS) and overall survival (OS) were recorded. The survival curves were plotted by Kaplan-Meier method and survival difference between patients with different LDH level was compared by log-rank test. Cox regression analysis was used to analyze prognostic factors for mortality. \u0000 \u0000 \u0000Results \u0000The objective response rate of the LDH normal group was 76.9% (60/78), and the elevated group was 71.4% (80/112), with no statistically significant difference (χ2=0.716, P=0.398). The disease control rate of the LDH normal group was 89.7% (70/78), and the elevated group was 85.7% (96/112), with no statistically significant difference (χ2=0.676, P=0.411). The median PFS of the LDH normal group was 11.5 months, and the elevated group was 9.7 months (χ2=5.92, P=0.015). The median OS was 31.0 months in the LDH normal group, and 26.1 months in the elevated LDH group (χ2=4.79, P=0.029). Both PFS and OS of patients with elevated LDH were shorter than those of patients with normal LDH. Cox multivariate regression analysis showed that tumor staging (HR=1.652, 95%CI: 1.386-2.259, P=0.018), PS score (HR=2.248, 95%CI: 1.507-3.846, P<0.001), carcino-embryonic antigen (CEA) level (HR=1.250, 95%CI: 1.066-1.703, P=0.037) and LDH level (HR=1.771, 95%CI: 1.324-1.947, P=0.015) were independent prognostic factors in patients with advanced NSCLC. \u0000 \u0000 \u0000Conclusion \u0000Pretreatment serum LDH can not affect the objective response rate and disease control rate of EGFR-TKI in the treatment of advanced NSCLC, but can affect the PFS and OS of patients. Pretreatment serum LDH is an independent prognostic factor. \u0000 \u0000 \u0000Key words: \u0000Lactate dehydrogenase; Carcinoma, non-small cell lung; Epidermal growth factor receptor-tyrosine kinase inhibitors; Prognosis","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"116 1","pages":"337-341"},"PeriodicalIF":0.0,"publicationDate":"2019-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80422120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Observation of efficacy of paclitaxel with concurrent radiotherapy in the treatment for nasopharyngeal carcinoma patients with liver metastasis","authors":"P. Zhou, Weisi Chen, Shuang Zhang, Bing Lin, Tao Pan, Sha Liu","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.06.002","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.06.002","url":null,"abstract":"Objective \u0000To investigate the efficacy, prognosis and safety of weekly paclitaxel with concurrent radiotherapy in nasopharyngeal carcinoma (NPC) patients with multiple liver metastases. \u0000 \u0000 \u0000Methods \u0000A total of 64 NPC patients with multiple liver metastases in First Affiliated Hospital of Hainan Medical University between January 2016 and January 2018 were recruited and randomly divided into experimental group (n=32) and control group (n=32) by the method of random number table. The patients in the two groups were given palliative radiotherapy with a median dose of 30 Gy. The experimental group used weekly paclitaxel (40 mg/m2) concurrent chemotherapy, cisplatin (40 mg/m2) in the control group. Paclitaxel and cisplatin were used weekly until the end of radiotherapy. The clinical efficacy and adverse effects between the two groups were compared. \u0000 \u0000 \u0000Results \u0000During the follow-up, 1 patient was lost to follow-up in the experimental group, complete remission (CR) in 6 cases (19.4%), partial remission (PR) in 9 cases (29.0%), stable disease (SD) in 7 cases (22.6%) and progressive disease (PD) in 9 cases (29.0%); 2 patients were lost to follow-up in the control group, CR in 4 cases (13.4%), PR in 10 cases (33.3%), SD in 9 cases (30.0%) and PD in 7 cases (23.3%). There was no significant difference between the two groups (Z=-0.060, P=0.952). The effective rates of the experimental group and the control group were 48.4% (15/31) and 46.7% (14/30) respectively, and the difference was not statistically significant (χ2=0.018, P=0.893); the tumor control rates were 71.0% (22/31) and 76.7% (23/30), with no statistically significant difference (χ2=0.256, P=0.613). The median survival time of the experimental group and the control group were 9.4 months and 8.9 months respectively, and the 1-year survival rates were 14.5% and 10.0%, with no significant difference (χ2=1.136, P=0.286). Among the adverse effects, the incidence rates of allergic reaction, neurotoxicity and cardiovascular toxicity in the experimental group were higher than those in the control group [18.8% (6/32) vs. 3.1% (1/32), 28.1% (9/32) vs. 15.6% (5/32), 31.3% (10/32) vs. 15.6% (5/32)], with no significant differences (χ2=2.566, P=0.109; χ2=1.463, P=0.226; χ2=2.177, P=0.140). The incidence rates of granulocyte decline, platelet decline, red blood cell decline, and impaired liver and kidney function in the experimental group were lower than those in the control group [56.3% (18/32) vs. 68.8% (22/32), 12.5% (4/32) vs. 21.9% (7/32), 15.6% (5/32) vs. 25.0% (8/32), 21.9% (7/32) vs. 28.1% (9/32)], with no significant differences (χ2=1.067, P=0.302; χ2=0.988, P=0.320; χ2=0.868, P=0.351; χ2=0.333, P=0.564). The incidence rates of nausea and vomiting was lower than that in the control group [(40.6% (13/32) vs. 78.1% (25/32)], with a significant difference (χ2=9.328, P=0.002). \u0000 \u0000 \u0000Conclusion \u0000Weekly paclitaxel with concurrent radiotherapy has equivalent efficacy to cisplatin and the adverse effects can","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"78 1","pages":"327-330"},"PeriodicalIF":0.0,"publicationDate":"2019-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89015254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of selective CDK4/6 inhibitors in solid cancers therapy","authors":"Bai-hong Zhang, Hong-yun Yue","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.06.007","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.06.007","url":null,"abstract":"Cyclin-dependent kinase (CDK) inhibitors have been approved for the treatment of ER+ /HER2- advanced breast cancer, and preclinical study and clinical trials are under way for multiple solid cancers. CDK4/6 inhibitors have shown good efficacy for human solid cancers, and it′s future development direction are biomarkers, drug resis-tance and combined therapy in the future. \u0000 \u0000 \u0000Key words: \u0000Neoplasms; Cyclin-dependent kinases; Therapeutics; Cell cycle","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"54 1","pages":"350-353"},"PeriodicalIF":0.0,"publicationDate":"2019-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89346867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}